Bruker (NASDAQ:BRKR) Issues Earnings Results

Bruker (NASDAQ:BRKR) released its quarterly earnings results on Wednesday. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.14, FiscalAI reports. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The company had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. During the same quarter in the prior year, the business posted $0.45 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year.

Here are the key takeaways from Bruker’s conference call:

• Margins and adjusted EPS improved sharply: Q3 non-GAAP operating margin rose 400 basis points to 16.3%, and diluted non-GAAP EPS increased 24% to $0.56, helped by cost savings and favorable product mix.
• Bookings point to improving demand: BSI book-to-bill remained above one for a fifth consecutive quarter, with year-to-date bookings and backlog up mid-single digits. Management cited strong China demand, a return to U.S. academic and government bookings growth, and more than 30% year-to-date growth in semiconductor metrology orders.
• Bruker reaffirmed its 2026 organic revenue growth outlook of 1%–2% and non-GAAP EPS range of $2.10–$2.15; it expects lower-mid-single-digit organic revenue growth in Q4. Management said 2027 should bring faster organic growth, further margin expansion, and double-digit EPS growth, while noting detailed guidance will come in February.
• Reported growth remained modest: Q3 organic revenue increased just 0.7%, while BSI organic revenue declined 0.4%, partly due to previously disclosed semiconductor instrument pushouts. GAAP results included a roughly $175 million non-cash goodwill impairment tied to Bruker Spatial Biology and a diluted loss per share of $0.81.

Bruker Trading Up 12.0%

NASDAQ BRKR traded up $6.78 on Wednesday, hitting $63.28. 4,945,591 shares of the company were exchanged, compared to its average volume of 2,366,428. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. Bruker has a twelve month low of $32.37 and a twelve month high of $68.98. The firm has a market capitalization of $9.64 billion, a P/E ratio of -90.31, a price-to-earnings-growth ratio of 1.70 and a beta of 1.26. The company’s 50 day moving average price is $58.81 and its 200-day moving average price is $50.41.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Analyst Ratings Changes

A number of analysts have commented on BRKR shares. Barclays boosted their price target on shares of Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. The Goldman Sachs Group upgraded shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Guggenheim upped their target price on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Citigroup decreased their price target on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $59.43.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the transaction, the vice president owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.20% of the stock is owned by corporate insiders.

Key Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported third-quarter earnings of $0.56 per share, above the $0.42 consensus estimate and up from $0.45 a year earlier. Revenue of $874 million also exceeded expectations of $865.16 million, with sales rising 1.6% year over year. The earnings and revenue beats are the clearest near-term catalysts for the shares. Read article
• Positive Sentiment: Bruker said U.S. academic-market demand returned in Q3 and is targeting double-digit EPS growth in fiscal 2027, suggesting a potential improvement in a market that had been an overhang. Read article
• Neutral Sentiment: For 2026, Bruker forecast revenue of $3.52 billion to $3.56 billion, putting the midpoint slightly below FactSet’s $3.56 billion estimate. Its non-GAAP EPS outlook of $2.10 to $2.15 brackets the $2.12 consensus, broadly aligning with expectations. Read article
• Negative Sentiment: A report highlighted a steep goodwill charge despite improved margins, raising a potential concern about reported results and earnings quality. Read article

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.